Harnessing AI in Healthcare: A Unique Opportunity for Diabetes Treatment in India

By Sumona Bose

January 11, 2024

The Rising Burden of Diabetes in India: A Unique Opportunity for AI

India’s escalating diabetes cases present a unique challenge, but also a unique opportunity. The vast amount of data available could be harnessed through electronic medical records, positioning India at the forefront of research in this area. The application of artificial intelligence (AI) and machine learning (ML) could provide valuable insights and help devise bespoke solutions.

Figure 1: Indian Map showing the distribution of Diabetes

 

AI and ML: A Game Changer in Chronic Disease Management

AI and ML are already making strides in chronic disease management, particularly diabetes. These technologies are being used to predict diabetes risk based on genomic data, diagnose diabetes using EHR data, and predict complications such as nephropathy and retinopathy. Google’s AI research unit, in collaboration with several Indian ophthalmology centres, has made significant advances in automated diagnosis and grading of diabetic retinopathy based on fundus photographs. The adoption of these technologies could dramatically increase the detection and early treatment of diabetic complications.

The Potential of AI and ML in India’s Healthcare System

The potential of AI and ML is particularly significant in India, where diabetes prevalence is estimated at 8-10%, with a slightly lower burden in rural areas compared to urban areas. However, the prevalence of diabetes in Delhi is estimated at around 27%, with 46% or more of the population having prediabetes. Such an early and extensive occurrence of diabetes could place a significant burden on the healthcare system.

AI and ML are only as good as the data used to generate this intelligence. India is sometimes referred to as a “country with no records”, highlighting the general lack of record-keeping as an essential part of medical practice. However, this burden of disease could be transformed into an opportunity if all data is harnessed in a usable form and AI and ML are used to generate insights and solutions specific to our population. A concerted and collective effort is needed by the government and large associations, like the Endocrine Society of India, to initiate data collections and research.

In conclusion, AI’s evolution in healthcare, particularly in the management of diabetes, offers a unique opportunity for India. With the right strategies and collaborations, AI could significantly improve the country’s healthcare system and contribute to better patient outcomes.

Reference url

Recent Posts

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

Tolebrutinib MS analysis
          

Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS

💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?

A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.

Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.

#SyenzaNews #HealthEconomics #MarketAccess

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.